It has been suggested that inhibition of ACACA may be useful in treating a variety of metabolic disorders, including metabolic syndrome, type 2 diabetes mellitus, and fatty liver disease (Harriman et al, 2016). This evidence concerns the gene ACACA and type 2 diabetes mellitus.